All News

In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.

Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.

As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.

How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.

At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.

Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.

In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.

Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.

Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.

A float pharmacist reflects on how practicing in different communities revealed that patients often have more in common than they first appear to.

Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss how an investigational meditope-enabled CAR T-cell platform could offer control through adapter dosing and the pharmacist’s role in its clinical development.

A lipidologist outlines how PREVENT, coronary calcium scoring, and restored LDL-C targets guide personalized lipid therapy and where pharmacists fit in.

When even federal guidance sparks debate, an expert advises pharmacists to consider the source and point patients to long-standing healthful eating.

As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.

The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss preclinical research on a meditope-enabled platform designed to redirect CAR T cells toward additional tumor targets and support their expansion after infusion.

Panelists explain how health systems can use the National Kidney Foundation’s CKDintercept initiative to build interdisciplinary, value-based kidney care, starting with small patient groups and setting time-bound treatment goals.

The cardiovascular-kidney-metabolic (CKM) framework can replace siloed care with comanagement across specialties, centered on an engaged patient and supported by making fuller use of clinical pharmacists.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

The innovation that frees a patient from the infusion chair is the innovation that asks pharmacists to replace, from a distance, everything that chair used to catch.

Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.

In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.